Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. März 2021 08:30 ET | Quelle: Claritas Pharmaceuticals, Inc.

Claritas Announces Appointment of Robert Farrell, J.D. as Chairman of the Company’s Board of Directors

SAN FRANCISCO and TORONTO, March 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
17. März 2021 08:30 ET | Quelle: Claritas Pharmaceuticals, Inc.

Claritas Announces Completion of Canine Toxicology Studies

SAN FRANCISCO and TORONTO, March 17, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
12. März 2021 08:30 ET | Quelle: Claritas Pharmaceuticals, Inc.

Claritas Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107

SAN FRANCISCO and TORONTO, March 12, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
08. März 2021 08:30 ET | Quelle: Claritas Pharmaceuticals, Inc.

Claritas Announces Formation of Nitric Oxide Scientific Advisory Board

SAN FRANCISCO and TORONTO, March 08, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
05. März 2021 08:30 ET | Quelle: Claritas Pharmaceuticals, Inc.

Claritas (formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea, Ph.D. to the Company’s Board of Directors

SAN FRANCISCO and TORONTO, March 05, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced the addition of Professor...
04. März 2021 08:30 ET | Quelle: Claritas Pharmaceuticals, Inc.

Claritas (formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of COVID-19 with Prophylactic R-107 Nasal Spray Designed to Provide Sustained Release of Nitric Oxide in the Nasal Cavities

SAN FRANCISCO and TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
03. März 2021 08:30 ET | Quelle: Claritas Pharmaceuticals, Inc.

Claritas (formerly Kalytera Therapeutics, Inc.) to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections

SAN FRANCISCO and TORONTO, March 03, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
02. März 2021 08:30 ET | Quelle: Claritas Pharmaceuticals, Inc.

Claritas (Formerly Kalytera Therapeutics) Cites Breakthrough Data by Massachusetts General Hospital and Others Demonstrating the Effectiveness of Nitric Oxide as a Potential Therapy for COVID-19 Infection and Validating the Potential of R-107 in this Indication

SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today...
01. März 2021 07:30 ET | Quelle: Claritas Pharmaceuticals, Inc.

Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections

SAN FRANCISCO and TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.), (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the "Company" or...
26. Februar 2021 07:30 ET | Quelle: Kalytera Therapeutics Inc.

Kalytera Announces Resumption of Trading on TSXV

SAN FRANCISCO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that its shares will resume...

Vorherige Seite

Nächste Seite